Company: STAA
Filing Date: 2025-09-26
Form Type: DEFA14A
Source: 0001193125-25-219844
Chunk: 16

Company: STAAR SURGICAL CO
Filing Date: 2025-09-26
Form: DEFA14A
Chunk 16
---
 definitive proxy. Reflects a burn down of distributor inventory. (1) Net sales declined FY23-FY25. STAAR believes China procedure volumes for EVO ICLs are essentially flat year to date, and some of the 2Q25 and 3Q25 volumes may have shifted to 1Q25 when STAAR saw stronger trends. STAAR believes China procedure volumes were positive year over year in 1Q25, softened during 2Q25, and have not improved so far in 3Q25. Quarterly Trends Do Not Signal a Return to Historical Levels EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

Combined with Alcon, STAAR will be better equipped to effectively compete. Global Competition Persists New Entrants in China Loong Crystal PR Lens NMPA approval in 2025 PRL (Phakic Refractive Lens) NMPA approval in 2020; next-gen pending Vision Pro Spheric / Toric NMPA approval pending EYECRYL Phakic IOL South America, EMEA, and APAC Launched in 2014 ARTISAN U.S., LATAM, South America, EMEA, APAC, and Australia (ARTIFLEX in certain regions) Launched in 2000 MPL (Medennium Phakic Lens) CE marked; clinical testing in China IPCL V2.0 LATAM, South America, EMEA, APAC, and Australia; approved in Japan in 2025 Launched in 2019 Rapidly Evolving Market While STAAR has successfully navigated the competitive landscape in the past, competition is increasing and the market is rapidly evolving China’s Green Channel regulatory pathway expedites registration for certain medical devices, leading to more local entrants and a rapidly evolving landscape Multiple competing lenses are progressing through the regulatory approval process, with recent developments signaling launches sooner than originally expected Greater market focus on phakic lenses increases the likelihood of continued investment and heightened competition Local players may enjoy selling and regulatory advantages EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

STAAR has a limited product offering, with nearly all of its Net Sales from EVO and EVO+ ICLs, which creates a heightened risk profile for STAAR While STAAR’s innovative ICL technology has a proven history of clinical